Patents by Inventor Elizabeth Sally Ward

Elizabeth Sally Ward has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11459396
    Abstract: The present disclosure includes a fusion protein, called a “Seldeg”, including a targeting component that specifically binds to a cell surface receptor or other cell surface molecule at near-neutral pH, and an antigen component fused directly or indirectly to the targeting component. The antigen component is configured to specifically bind a target antigen-specific antibody. The present disclosure also includes a method of depleting a target antigen-specific antibody from a patient by administering to the patient a Seldeg having an antigen component configured to specifically bind the target antigen-specific antibody.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: October 4, 2022
    Assignee: THE TEXAS A&M UNIVERSITY SYSTEM
    Inventors: Elizabeth Sally Ward Ober, Venkata Siva Charan Devanaboyina, Raimund Johannes Ober
  • Publication number: 20200031948
    Abstract: The present disclosure includes a fusion protein, called a “Seldeg”, including a targeting component that specifically binds to a cell surface receptor or other cell surface molecule at near-neutral pH, and an antigen component fused directly or indirectly to the targeting component. The antigen component is configured to specifically bind a target antigen-specific antibody. The present disclosure also includes a method of depleting a target antigen-specific antibody from a patient by administering to the patient a Seldeg having an antigen component configured to specifically bind the target antigen-specific antibody.
    Type: Application
    Filed: December 1, 2017
    Publication date: January 30, 2020
    Applicant: THE TEXAS A&M UNIVERSITY SYSTEM
    Inventors: Elizabeth Sally Ward OBER, Venkata Siva Charan DEVANABOYINA, Raimund Johannes OBER
  • Publication number: 20190381183
    Abstract: Endolysosomal targeting conjugates that are engineered to deliver cargo molecules such as cytotoxic drugs or imaging labels with improved efficiency to late endosomes and/or lysosomes in target cells such as tumor cells are described. The endolysosomal targeting conjugate includes a targeting component and a cargo component. The targeting component is configured to bind to a cell surface molecule of a target cell and the cargo component includes a cargo molecule. The targeting component and the cargo component may be fused by a covalent bond or associated by a non-covalent bond. The targeting component may bind to the cell surface molecule or the cargo component with higher affinity in the extracellular space than in an endolysosomal compartment of the target cell.
    Type: Application
    Filed: January 17, 2018
    Publication date: December 19, 2019
    Applicant: THE TEXAS A&M UNIVERSITY SYSTEM
    Inventors: Elizabeth Sally WARD OBER, Raimund Johannes OBER, Jeffrey Che-Wei KANG, Wei SUN, Ran LI
  • Patent number: 9562100
    Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: February 7, 2017
    Assignees: MedImmune LLC, Board of Regents, The University of Texas System
    Inventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward Ober
  • Publication number: 20140377181
    Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
    Type: Application
    Filed: June 20, 2014
    Publication date: December 25, 2014
    Applicants: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, MEDIMMUNE, LLC
    Inventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward Ober
  • Patent number: 8795661
    Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: August 5, 2014
    Assignees: MedImmune, LLC, Board of Regents, The University of Texas System
    Inventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward Ober
  • Publication number: 20130272964
    Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
    Type: Application
    Filed: May 20, 2013
    Publication date: October 17, 2013
    Inventors: WILLIAM DALL'ACQUA, LESLIE S. JOHNSON, ELIZABETH SALLY WARD OBER
  • Patent number: 8475792
    Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: July 2, 2013
    Assignees: MedImmune, LLC, Board of Regents, The Texas University System
    Inventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward Ober
  • Patent number: 8323962
    Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
    Type: Grant
    Filed: July 27, 2011
    Date of Patent: December 4, 2012
    Assignees: MedImmune, LLC, Board of Regents, The University of Texas System
    Inventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward
  • Publication number: 20110311454
    Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
    Type: Application
    Filed: July 27, 2011
    Publication date: December 22, 2011
    Applicants: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, MEDIMMUNE, LLC
    Inventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward
  • Patent number: 8012476
    Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
    Type: Grant
    Filed: January 21, 2010
    Date of Patent: September 6, 2011
    Assignees: MedImmune, LLC, Board of Regents, The University of Texas System
    Inventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward
  • Publication number: 20100189718
    Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
    Type: Application
    Filed: January 21, 2010
    Publication date: July 29, 2010
    Inventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward
  • Patent number: 7704497
    Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
    Type: Grant
    Filed: January 3, 2007
    Date of Patent: April 27, 2010
    Assignees: MedImmune, LLC, Board of Regents, The University of Texas System
    Inventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward
  • Patent number: 7670600
    Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
    Type: Grant
    Filed: April 3, 2006
    Date of Patent: March 2, 2010
    Assignees: MedImmine, LLC, Board of Regents, The University of Texas System
    Inventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward
  • Patent number: 7306907
    Abstract: The present invention relates to single domain ligands derived from molecules in the immunoglobulin (Ig) superfamily, receptors comprising at least one such ligand, methods for cloning, amplifying and expressing DNA sequences encoding such ligands, preferably using the polymerase chain reaction, methods for the use of said DNA sequences in the production of Ig-type molecules and said ligands or receptors, and the use of said ligands or receptors in therapy, diagnosis or catalysis.
    Type: Grant
    Filed: November 8, 2002
    Date of Patent: December 11, 2007
    Assignee: Cambridge Antibody Technology Limited
    Inventors: Gregory Paul Winter, Elizabeth Sally Ward, Detlef Güssow
  • Patent number: 7083784
    Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulin, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
    Type: Grant
    Filed: December 12, 2001
    Date of Patent: August 1, 2006
    Assignee: MedImmune, Inc.
    Inventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward
  • Patent number: 6821505
    Abstract: Disclosed are recombinant vectors encoding immunoglobulin-like domains and portions thereof, such as antibody Fc-hinge fragments, subfragments and mutant domains with extended biological half lives. Methods of producing large quantities of such domains, heterodimers, and fusion proteins following expression by host cells are also reported. Described are antibody Fc and Fc-hinge domains, which have the same in vivo stability as intact antibodies; and domains engineered to have increased in vivo half lives. These DNA constructs and protein domains will be useful as templates for in vitro mutagenesis and high resolution structural studies; for immunization and vaccination; and for the production of recombinant antibodies or chimeric proteins with increased stability and longevity for therapeutic and diagnostic uses.
    Type: Grant
    Filed: August 20, 2001
    Date of Patent: November 23, 2004
    Assignee: Board of Regents, The University of Texas System
    Inventor: Elizabeth Sally Ward
  • Publication number: 20040110941
    Abstract: The present invention relates to single domain ligands derived from molecules in the immunoglobulin (Ig) superfamily, receptors comprising at least one such ligand, methods for cloning, amplifying and expressing DNA sequences encoding such ligands, preferably using the polymerase chain reaction, methods for the use of said DNA sequences in the productions of Ig-type molecules and said ligands or receptors, and the use of said ligand or receptors in therapy, diagnosis or catalysis.
    Type: Application
    Filed: November 8, 2002
    Publication date: June 10, 2004
    Applicant: Medical Research Council
    Inventors: Gregory Paul WINTER, Elizabeth Sally WARD, Detlef GUSSOW
  • Publication number: 20030190311
    Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulin, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
    Type: Application
    Filed: December 12, 2001
    Publication date: October 9, 2003
    Inventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward
  • Publication number: 20030130496
    Abstract: The present invention relates to single domain ligands derived from molecules in the immunoglobulin (Ig) superfamily, receptors comprising at least one such ligand, methods for cloning, amplifying and expressing DNA sequences encoding such ligands, preferably using the polymerase chain reaction, methods for the use of said DNA sequences in the production of Ig-type molecules and said ligands or receptors, and the use of said ligands or receptors in therapy, diagnosis or catalysis.
    Type: Application
    Filed: November 8, 2002
    Publication date: July 10, 2003
    Applicant: Medical Research Council
    Inventors: Gregory Paul Winter, Elizabeth Sally Ward, Detlef Gussow